ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 59 Shown
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017 2 comments / Last Comment: 4/24/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017 2 comments / Last Comment: 2/21/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016 1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016 3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016 6 comments / Last Comment: 6/25/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015 2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
  • How I Use Resistance Testing to Guide Management of Patients With Chronic Hepatitis C

    Mark S. Sulkowski MD - 9/15/2015 14 comments / Last Comment: 6/25/2016
    Using a recent case patient, I outline my current approach to using HCV resistance testing to select therapy in patients who have previously received an HCV NS5A inhibitor.
  • My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection

    Norah Terrault MD, MPH - 9/10/2015 10 comments / Last Comment: 6/25/2016
    Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
  • Patients With Renal Disease: One of the Remaining Challenges in HCV Therapy

    Nancy Reau MD - 8/25/2015 31 comments / Last Comment: 6/25/2016
    A recent patient discussion highlighted important questions about how to approach HCV infection in renal disease.
10 of 59 Shown
Show 10 More
Loading...